Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATN-224 and Bortezomib in Relapsed/Refractory Multiple Myeloma
NCT00352742Phase 2Terminated
- Sponsor
- Attenuon LLC
- Start
- Jun 2006
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atn-224 in multiple myeloma (MM), sponsored by Attenuon LLC. Primary endpoints: Determine a safe dose of ATN-224 and bortezomib and Efficacy. Started Jun 2006; status: terminated.
02
Drugs
atn-224
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00352742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00352742.